Recent Progress of Small Molecule Menin–MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia

Challenges and opportunities in targeting the menin-MLL interaction.

Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax

Biomedicines, Free Full-Text

Challenges and opportunities in targeting the menin-MLL interaction.

Recent Progress of Small Molecule Menin–MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia

Small molecule inhibitors for acute myeloid leukemia: where is the field heading?

Molecules, Free Full-Text

A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1, Cancer Cell International

Challenges and opportunities in targeting the menin-MLL interaction. - Abstract - Europe PMC

Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia - ScienceDirect

Recent Progress of Small Molecule Menin–MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia

Recent Progress of Small Molecule Menin–MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia

Frontiers Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia